Handan Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Handan Kaya has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Erkin Aribal
Department of Radiology, Acibadem University School of Medicine, Istanbul, Turkey
8 shared publications - Mustafa Umit Ugurlu
Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey
5 shared publications - Mustafa Akkiprik
Department of Medical Biology, School of Medicine, Marmara University, Istanbul, Turkey
4 shared publications - Bahadir Mahmut Gulluoglu
Breast and Endocrine Surgery Unit, Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey
3 shared publications - Gökçe Güllü Amuran
Department of Medical Biology, School of Medicine, Marmara University, Istanbul, Turkey
3 shared publications - Onur Bugdayci
Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey
3 shared publications
Latest Publications
- 23 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1-13
NOS1AP: a potential subtype-specific dual role as a tumor suppressor and oncogene in breast cancer subtypes
Background NOS1AP/CAPON has been associated with neurological and cardiovascular diseases, but it has recently gained significant attention in cancer research. A limited number of studies conducted on breast cancer (BC) suggest that NOS1AP may possess both tumor suppressive and oncogenic potential. Methods and results This study is the first to investigate the relationship between NOS1AP and EMT (Epithelial-Mesenchymal Transition) in BC tissues and within distinct BC subtypes. Additionally, it provides a pioneering analysis of NOS1AP associations with Hippo pathway components across BC subtypes. The expression levels of NOS1AP, Hippo pathway genes, and EMT markers in primary tissues from different BC subtypes were analyzed using RT-PCR. While NOS1AP expression was reduced in basal BC tissues compared to normal adjacent tissues (NAT), in luminal B BC tissues, only NOS1AP and CDH1 expression showed a significant increase (p < 0.05). Correlation analyses suggest a potential association between NOS1AP, EMT markers, and components of the Hippo pathway. Bioinformatics analysis of overall survival (OS) curves revealed that high NOS1AP expression is associated with prolonged OS, irrespective of BC subtype. Conclusions These findings suggest that NOS1AP may play a dual role in a subtype-specific manner, potentially serving as a subtype-specific biomarker.
- 23 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1-13
NOS1AP: a potential subtype-specific dual role as a tumor suppressor and oncogene in breast cancer subtypes
Background NOS1AP/CAPON has been associated with neurological and cardiovascular diseases, but it has recently gained significant attention in cancer research. A limited number of studies conducted on breast cancer (BC) suggest that NOS1AP may possess both tumor suppressive and oncogenic potential. Methods and results This study is the first to investigate the relationship between NOS1AP and EMT (Epithelial-Mesenchymal Transition) in BC tissues and within distinct BC subtypes. Additionally, it provides a pioneering analysis of NOS1AP associations with Hippo pathway components across BC subtypes. The expression levels of NOS1AP, Hippo pathway genes, and EMT markers in primary tissues from different BC subtypes were analyzed using RT-PCR. While NOS1AP expression was reduced in basal BC tissues compared to normal adjacent tissues (NAT), in luminal B BC tissues, only NOS1AP and CDH1 expression showed a significant increase (p < 0.05). Correlation analyses suggest a potential association between NOS1AP, EMT markers, and components of the Hippo pathway. Bioinformatics analysis of overall survival (OS) curves revealed that high NOS1AP expression is associated with prolonged OS, irrespective of BC subtype. Conclusions These findings suggest that NOS1AP may play a dual role in a subtype-specific manner, potentially serving as a subtype-specific biomarker.
- 14 March 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
Evaluation of High-risk (B3) Breast Lesions on MRI: The Role of Diffusion-weighted Imaging and Texture Analysis Features in Predicting Upgrade to Malignancy
Objective: This study aimed to investigate the potential malignancy associated with high-risk breast lesions using breast magnetic resonance imaging (MRI) characteristics, apparent diffusion coefficient (ADC) measurements, and texture analysis parameters. Methods: This retrospective study included 40 patients with 41 lesions diagnosed as high-risk lesions after needle biopsy. All the patients underwent surgery. Based on the histopathologic results of the surgical excision, the patients were divided into 2 groups: those diagnosed with malignancy and those who were not. The MRI characteristics of the lesions were recorded. The ADC values of the lesions were measured. Textural analysis of the lesions was also performed. Results: Fourteen lesions (34.1%) were upgraded to malignancy. The median ADCmean values in the malignant group were 1.114 × 10−3 versus 1.383×10−3 mm2/s in the nonmalignant group, which was statistically significant (P < 0.001). The cutoff value for the mean ADC was 1.163 ×10−3 mm2/s. The sensitivity and specificity were 71.4% and 85.2%, respectively. Among the texture analysis parameters, kurtosis values obtained from images on the ADC map and the first subtracted dynamic contrast-enhanced (DCE) series and contrast values obtained from images on the second subtracted DCE series were found to be statistically significant (P = 0.016, P = 0.019, and P = 0.045, respectively) between the malignant and nonmalignant groups. Conclusions: ADC measurements and texture analysis parameters provide useful diagnostic information for determining which high-risk breast lesions will progress to malignancy.
- 14 March 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
Evaluation of High-risk (B3) Breast Lesions on MRI: The Role of Diffusion-weighted Imaging and Texture Analysis Features in Predicting Upgrade to Malignancy
Objective: This study aimed to investigate the potential malignancy associated with high-risk breast lesions using breast magnetic resonance imaging (MRI) characteristics, apparent diffusion coefficient (ADC) measurements, and texture analysis parameters. Methods: This retrospective study included 40 patients with 41 lesions diagnosed as high-risk lesions after needle biopsy. All the patients underwent surgery. Based on the histopathologic results of the surgical excision, the patients were divided into 2 groups: those diagnosed with malignancy and those who were not. The MRI characteristics of the lesions were recorded. The ADC values of the lesions were measured. Textural analysis of the lesions was also performed. Results: Fourteen lesions (34.1%) were upgraded to malignancy. The median ADCmean values in the malignant group were 1.114 × 10−3 versus 1.383×10−3 mm2/s in the nonmalignant group, which was statistically significant (P < 0.001). The cutoff value for the mean ADC was 1.163 ×10−3 mm2/s. The sensitivity and specificity were 71.4% and 85.2%, respectively. Among the texture analysis parameters, kurtosis values obtained from images on the ADC map and the first subtracted dynamic contrast-enhanced (DCE) series and contrast values obtained from images on the second subtracted DCE series were found to be statistically significant (P = 0.016, P = 0.019, and P = 0.045, respectively) between the malignant and nonmalignant groups. Conclusions: ADC measurements and texture analysis parameters provide useful diagnostic information for determining which high-risk breast lesions will progress to malignancy.
- Open Access
- 29 January 2025
- Published by Marmara University in Marmara Medical Journal
- Vol. 38 (1) , 76-83
Succinate dehydrogenase-B fluorescence in situ hybridization in pheochromocytoma-paragangliomas
Objective: Preoperative identification of familial pheochromocytoma and paraganglioma (PPGL) is crucial, yet often overlooked, leading to missed diagnoses. Typically, succinate dehydrogenase-B (SDHB) and fumarate hydratase (FH) tests are applied postoperatively to confirm familial links and assess prognosis. However, routine preoperative multidisciplinary collaboration is limited, causing delayed screening requests. Consequently, routine SDHB and FH immunohistochemistry (IHC) testing is not widely practiced. This study introduces SDHB fluorescence in situ hybridization (FISH) as a diagnostic tool, akin to HER2 IHC-FISH testing in gastric carcinomas. Materials and Methods: Succinate dehydrogenase-B and FH IHC were conducted on 43 cases. FISH analysis was performed for 28 cases with suspected familial origin or SDHB IHC loss to determine whether the protein loss was due to chromosomal changes. Results: Complete SDHB IHC loss occurred in 8 cases, partial loss in 4, and preservation in 31. Complete FH loss occurred in 10 cases. FISH analysis revealed chromosomal breaks in 20 cases (71.4%), including those with SDHB/FH IHC loss or positive clinical history. Ten cases (35.7%) showed a “red-signal only” pattern, suggesting further genetic testing. Conclusion: Succinate dehydrogenase-B FISH serves as a cost-effective tool for early PPGL diagnosis, complementing SDHB and FH IHC results. It can help identify cases that need genetic testing, even when IHC results are preserved.
- 29 January 2025
- Published by Marmara University in Marmara Medical Journal
- Vol. 38 (1) , 76-83
Open AccessSuccinate dehydrogenase-B fluorescence in situ hybridization in pheochromocytoma-paragangliomas
Objective: Preoperative identification of familial pheochromocytoma and paraganglioma (PPGL) is crucial, yet often overlooked, leading to missed diagnoses. Typically, succinate dehydrogenase-B (SDHB) and fumarate hydratase (FH) tests are applied postoperatively to confirm familial links and assess prognosis. However, routine preoperative multidisciplinary collaboration is limited, causing delayed screening requests. Consequently, routine SDHB and FH immunohistochemistry (IHC) testing is not widely practiced. This study introduces SDHB fluorescence in situ hybridization (FISH) as a diagnostic tool, akin to HER2 IHC-FISH testing in gastric carcinomas. Materials and Methods: Succinate dehydrogenase-B and FH IHC were conducted on 43 cases. FISH analysis was performed for 28 cases with suspected familial origin or SDHB IHC loss to determine whether the protein loss was due to chromosomal changes. Results: Complete SDHB IHC loss occurred in 8 cases, partial loss in 4, and preservation in 31. Complete FH loss occurred in 10 cases. FISH analysis revealed chromosomal breaks in 20 cases (71.4%), including those with SDHB/FH IHC loss or positive clinical history. Ten cases (35.7%) showed a “red-signal only” pattern, suggesting further genetic testing. Conclusion: Succinate dehydrogenase-B FISH serves as a cost-effective tool for early PPGL diagnosis, complementing SDHB and FH IHC results. It can help identify cases that need genetic testing, even when IHC results are preserved.
- Open Access
- 31 May 2024
- Published by Marmara University in Marmara Medical Journal
- Vol. 37 (2) , 178-184
Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements
Objective: Breast cancer is the most common and deadly female cancer. In breast cancer cases, survival is closely related to muscle mass, which is one of the components of body composition. Our aim was to investigate the usefulness of computed-tomography (CT)- based pectoral muscle measurements in detecting sarcopenia in patients with non-metastatic breast cancer and the relationship of these measurements with survival. Patients and Methods: Our study included 62 adult female breast cancer cases diagnosed with breast cancer between January 2012 and January 2018 and without metastasis in positron emission tomography/CT (PET/CT) examination obtained for pre-treatment staging. To evaluate sarcopenia, skeletal muscle index (SMI) and pectoral muscle index (PMI) were calculated by measuring pectoral muscle area and skeletal muscle area at L3 vertebra level on PET/CT images. Results: Deceased patients were significantly older (Median=73.90, IQR=27.04) than surviving patients (Median=54.60, IQR=13.37, p=0.025) and were diagnosed with cancer later in life (Median=63.92 IQR=30.16’ vs. Median=47.51 IQR=15.0, p=0.030). When the threshold of 31 cm2/m2 was selected, there was a statistically significant difference in survival between sarcopenic and non-sarcopenic groups (p=0.031). Conclusion: In conclusion, the presence of sarcopenia in female breast cancer cases is a parameter that affects survival and can be measured using radiological imaging methods. In addition to the measurements accepted in the literature regarding sarcopenia, pectoral muscle measurements can be chosen as an alternative method in the diagnosis of sarcopenia.
- 31 May 2024
- Published by Marmara University in Marmara Medical Journal
- Vol. 37 (2) , 178-184
Open AccessEvaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements
Objective: Breast cancer is the most common and deadly female cancer. In breast cancer cases, survival is closely related to muscle mass, which is one of the components of body composition. Our aim was to investigate the usefulness of computed-tomography (CT)- based pectoral muscle measurements in detecting sarcopenia in patients with non-metastatic breast cancer and the relationship of these measurements with survival. Patients and Methods: Our study included 62 adult female breast cancer cases diagnosed with breast cancer between January 2012 and January 2018 and without metastasis in positron emission tomography/CT (PET/CT) examination obtained for pre-treatment staging. To evaluate sarcopenia, skeletal muscle index (SMI) and pectoral muscle index (PMI) were calculated by measuring pectoral muscle area and skeletal muscle area at L3 vertebra level on PET/CT images. Results: Deceased patients were significantly older (Median=73.90, IQR=27.04) than surviving patients (Median=54.60, IQR=13.37, p=0.025) and were diagnosed with cancer later in life (Median=63.92 IQR=30.16’ vs. Median=47.51 IQR=15.0, p=0.030). When the threshold of 31 cm2/m2 was selected, there was a statistically significant difference in survival between sarcopenic and non-sarcopenic groups (p=0.031). Conclusion: In conclusion, the presence of sarcopenia in female breast cancer cases is a parameter that affects survival and can be measured using radiological imaging methods. In addition to the measurements accepted in the literature regarding sarcopenia, pectoral muscle measurements can be chosen as an alternative method in the diagnosis of sarcopenia.
- 8 December 2022
- Published by Wiley in Histopathology
- Vol. 82 (1) , 53-69
Breast lesions with myoepithelial phenotype
Myoepithelial cells (MECs) constitute a continuous layer of cells surrounding the breast glands, localised between the epithelial cells (ECs) and the basal membrane. MECs play important roles in normal mammary gland as they produce basal membrane and stimulate secretion. During neoplastic transformation, MECs act as a barrier preventing stromal invasion. MECs themselves can undergo a great variety of changes, ranging from hyperplastic to metaplastic, to neoplastic, and giving rise to a wide spectrum of morphological pictures sometimes difficult to interpret on routine diagnoses. Several benign and malignant breast tumours can present features of MECs differentiation. As these latter tumours are quite infrequent, the purpose of the present study is to offer a review of the morphological spectrum of MECs lesions, with correlations to prognosis.
- 8 December 2022
- Published by Wiley in Histopathology
- Vol. 82 (1) , 53-69
Breast lesions with myoepithelial phenotype
Myoepithelial cells (MECs) constitute a continuous layer of cells surrounding the breast glands, localised between the epithelial cells (ECs) and the basal membrane. MECs play important roles in normal mammary gland as they produce basal membrane and stimulate secretion. During neoplastic transformation, MECs act as a barrier preventing stromal invasion. MECs themselves can undergo a great variety of changes, ranging from hyperplastic to metaplastic, to neoplastic, and giving rise to a wide spectrum of morphological pictures sometimes difficult to interpret on routine diagnoses. Several benign and malignant breast tumours can present features of MECs differentiation. As these latter tumours are quite infrequent, the purpose of the present study is to offer a review of the morphological spectrum of MECs lesions, with correlations to prognosis.
- 16 September 2020
- Published by Springer Nature in European Radiology
- Vol. 31 (3) , 1718-1726
The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: a prospective multicenter study
Objectives To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography. Methods In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings. Results Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively. Conclusions In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade. Key Points • All invasive cancer cases and 87.8% of all in situ cancer cases were detected with MRI, showing a low false-negative rate of 4.7%. • Dynamic contrast-enhanced MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are predominantly low-to-medium grade. • If a decision for biopsy were made based on MRI findings in mammography-detected microcalcifications in this study, biopsy would not be performed to 119 cases (26.8%).
- 16 September 2020
- Published by Springer Nature in European Radiology
- Vol. 31 (3) , 1718-1726
The value of MRI contrast enhancement in biopsy decision of suspicious mammographic microcalcifications: a prospective multicenter study
Objectives To investigate the inclusion of breast MRI in radiological assessment of suspicious, isolated microcalcifications detected with mammography. Methods In this prospective, multicenter study, cases with isolated microcalcifications in screening mammography were examined with dynamic contrast-enhanced MRI (DCE-MRI) before biopsy, and contrast enhancement of the relevant calcification localization was accepted as a positive finding on MRI. Six experienced breast radiologists evaluated the images and performed the biopsies. Imaging findings and histopathological results were recorded. Sensitivity, specificity, NPV, and PPV of breast MRI were calculated and compared with histopathological findings. Results Suspicious microcalcifications, which were detected by screening mammograms of 444 women, were evaluated. Of these, 276 (62.2%) were diagnosed as benign and 168 (37.8%) as malignant. Contrast enhancement was present in microcalcification localization in 325 (73.2%) of the cases. DCE-MRI was positive in all 102 invasive carcinomas and in 58 (87.9%) of 66 DCIS cases. MRI resulted in false negatives in eight DCIS cases; one was high grade and the other seven were low-to-medium grade. The false-negative rate of DCE-MRI was 4.76%. The sensitivity, specificity, PPV, and NPV for DCE-MRI for mammography-detected suspicious microcalcifications were 95.2%, 40.2%, 49.2%, and 93.3%, respectively. Conclusions In this study, all invasive cancers and all DCIS except eight cases (12.1%) were detected with DCE-MRI. DCE-MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are of low-to-medium grade. Key Points • All invasive cancer cases and 87.8% of all in situ cancer cases were detected with MRI, showing a low false-negative rate of 4.7%. • Dynamic contrast-enhanced MRI can be used in the decision-making algorithm to decrease the number of biopsies in mammography-detected suspicious calcifications, with a tradeoff for overlooking a small number of DCIS cases that are predominantly low-to-medium grade. • If a decision for biopsy were made based on MRI findings in mammography-detected microcalcifications in this study, biopsy would not be performed to 119 cases (26.8%).
- 17 July 2020
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 26 (4) , 2733-2745
Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma
Tumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study, CD8, FOXP3, CD163, PD-L1/SP142 and PD-L1/SP263 antibodies were examined in a sample of 51 TNBC cases. Patients who received neoadjuvant therapy were excluded. CD8, FOXP3 and CD163 antibodies were evaluated separately in intratumoral area (ITA) and tumor stroma (TS). PD-L1 status was also examined in tumor cells (TC) and immune cells (IC) using both SP142 and SP263 antibodies. In multivariate Cox regressions, the only antibody that was found to be significantly associated with survival was SP142. SP142-positivity in TC and IC was related to increased overall survival. Higher CD163 expression in ITA and SP263-positivity in IC were associated with younger age. Lymphatic/angioinvasion was more frequent in cases with negative/low CD8 and FOXP3 expressions. Moreover, metastatic axillary lymph node(s) was associated with negative/low FOXP3 expression in TS. CD8, FOXP3, CD163, SP142 and SP263 expressions were positively correlated with each other, except a mild discordance caused by CD163 in ITA. Although PD-L1 status with both SP142 and SP263 antibodies were concordant in the majority of cases, 33.3% and 13.7% of the cases showed SP142-negative/SP263-positive pattern in TC and IC respectively. In conclusion, we suggest that composition, density and localization of the immune cells and the check point molecules are important prognostic parameters in TNBC. Immunohistochemistry can be used as an accessible and less expensive tool to demonstrate TIME.
- 17 July 2020
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 26 (4) , 2733-2745
Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma
Tumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study, CD8, FOXP3, CD163, PD-L1/SP142 and PD-L1/SP263 antibodies were examined in a sample of 51 TNBC cases. Patients who received neoadjuvant therapy were excluded. CD8, FOXP3 and CD163 antibodies were evaluated separately in intratumoral area (ITA) and tumor stroma (TS). PD-L1 status was also examined in tumor cells (TC) and immune cells (IC) using both SP142 and SP263 antibodies. In multivariate Cox regressions, the only antibody that was found to be significantly associated with survival was SP142. SP142-positivity in TC and IC was related to increased overall survival. Higher CD163 expression in ITA and SP263-positivity in IC were associated with younger age. Lymphatic/angioinvasion was more frequent in cases with negative/low CD8 and FOXP3 expressions. Moreover, metastatic axillary lymph node(s) was associated with negative/low FOXP3 expression in TS. CD8, FOXP3, CD163, SP142 and SP263 expressions were positively correlated with each other, except a mild discordance caused by CD163 in ITA. Although PD-L1 status with both SP142 and SP263 antibodies were concordant in the majority of cases, 33.3% and 13.7% of the cases showed SP142-negative/SP263-positive pattern in TC and IC respectively. In conclusion, we suggest that composition, density and localization of the immune cells and the check point molecules are important prognostic parameters in TNBC. Immunohistochemistry can be used as an accessible and less expensive tool to demonstrate TIME.
- 1 December 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (12) , 2279-2286
Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature
- 1 December 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (12) , 2279-2286
Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature
- 27 October 2019
- Published by Springer Nature
- p. 90-91
Ductal Adenoma